The startup develops biopharmaceutical drugs, including ecopipam, aimed at diagnosing and treating central nervous system disorders such as Tourette Syndrome and fluency disorders. Their focus is on providing effective treatment options for patients with rare neurological conditions that currently have limited or no therapeutic alternatives.
Funding
$382.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many central nervous system disorders, such as Tourette Syndrome, have limited or no effective treatment options, leaving patients with debilitating symptoms and reduced quality of life. Current therapeutic approaches often fail to adequately address the underlying neurobiological mechanisms or may be associated with significant side effects.
Solution
Emalex Biosciences is developing a new class of biopharmaceutical drugs, including their lead candidate ecopipam, for the treatment of central nervous system disorders with a focus on Tourette Syndrome. Ecopipam is a selective dopamine-1 receptor antagonist being investigated as a potential treatment to reduce tic severity in both pediatric and adult patients. The drug's mechanism of action targets the underlying neurocircuitry of Tourette Syndrome without exacerbating common psychiatric comorbidities. Emalex Biosciences is currently conducting late-stage clinical studies to evaluate the safety and efficacy of ecopipam, with the goal of providing a novel therapeutic option for patients with limited treatment alternatives. Topline data from Phase 3 studies has shown statistical significance between ecopipam and placebo in reducing tic severity.
Target Audience
The primary target audience includes individuals with Tourette Syndrome and other central nervous system disorders, as well as their families and healthcare providers seeking new treatment options.
Features
- Ecopipam: A selective dopamine-1 receptor antagonist
- Focus on central nervous system disorders, particularly Tourette Syndrome
- Clinical-stage development with ongoing Phase 3 studies
- Potential to reduce tic severity in pediatric and adult patients
- Designed to avoid exacerbating common psychiatric comorbidities